	US 12,264,365 B2
	Polynucleotides for amplification and detection of SARS-CoV-2
Nadya Andini, Livermore, CA (US); Kathy Chiu, Irvine, CA (US); Xuewen Jiang, Menlo Park, CA (US); and Hédia Maamar, San Jose, CA (US)
Assigned to Talis Biomedical Corporation, Chicago, IL (US)
Filed by Talis Biomedical Corporation, Chicago, IL (US)
Filed on Jun. 25, 2020, as Appl. No. 16/912,462.
Claims priority of provisional application 63/009,803, filed on Apr. 14, 2020.
Claims priority of provisional application 62/993,523, filed on Mar. 23, 2020.
Prior Publication US 2021/0292854 A1, Sep. 23, 2021
Int. Cl. C12Q 1/6876 (2018.01); C12Q 1/6813 (2018.01); C12Q 1/6844 (2018.01); C12Q 1/70 (2006.01)

CPC C12Q 1/6876 (2013.01) [C12Q 1/6813 (2013.01); C12Q 1/6844 (2013.01); C12Q 1/70 (2013.01); C12Q 2521/101 (2013.01); C12Q 2521/107 (2013.01); C12Q 2531/119 (2013.01); C12Q 2600/112 (2013.01)]

24 Claims

1. A composition comprising a set of polynucleotides comprising:

a primer set comprising a forward outer primer comprising SEQ ID NO: 63, a backward outer primer comprising SEQ ID NO: 86, a forward inner primer comprising SEQ ID NO: 65, a backward inner primer comprising SEQ ID NO: 87, a forward loop primer comprising SEQ ID NO: 67, and a backward loop primer comprising SEQ ID NO: 88.